Celprogen

Product Search:

CELPROGEN is a biotechnology company developing stem cell research and therapeutics products for regenerative medicine in cardiology, oncology, diabetes & neurology.

CELPROGEN provides novel molecular diagnostics and therapeutic product development solutions for Biotechnology, Pharmaceutical, Invitro diagnostics and academic partnership for drug discovery.

	The Therapeutics Division		The Life Science Division		The Device Division
	Has focused its Drug Discovery efforts in the development of Pharmaceutical agents and Drugs in the following categories: Cardiovascular, Diabetes, Neurological, Renal and Metabolic disorders.		Provides research tools & solutions including the following categories: assays, enzymes, antibodies, antigens, stem cells, Tissue culture expansion and differentiation media, primary and established cell cultures, tumor markers, cardiac markers, proteomic and genomic reagents and assay systems to life science research communities in both academic and pharmaceutical institutes.		Provides novel ELISA based assay, protein array, DNA array and cellular based assay systems that are cost effective for Research and Invitro diagnostics Indutstries.

Calcium Ratio Measurement of Cardiomiocyte in Culture - 3D Video

Click to view

................................................................................................................

Mouse Endothelial Cells in 3D Video Clip

Click to view

................................................................................................................

Cardiomyocyte 10x Day 9 Video Clip

Click to view

The therapeutic pipeline consists of the following drug development projects in their pre-clinical phase of development:

» CPG23CARD - Cholesterol lowering agent/drug.

» CPG23DIAB - Glucose lowering agent/drug for Type 1&2 diabetes.

» CPG23STEM - Adult stem cells that were trans-differentiated to β-Islets of Langerhan Cells to produce insulin. Pre-clinical invitro data has great promise for cellular based therapeutics for Type 1 diabetes.

» CPG23NEUR - Adult stem cells that were trans-differentiated to neuronal cells, pre-clinical invitro data has promise for cellular based therapeutics for neurologial disorders.

» CPG23PANC - Dendritic cell/peptide vaccine for pancreatic cancer